GT Biopharma Completes Dosing of First Patient in Phase 1/2 Trial of GTB-3550
News
GT Biopharma has successfully completed dosing of the first patient participating in its Phase 1/2 clinical trial of GTB-3550 (OXS-3550), the company’s experimental treatment for relapsed or refractory acute myeloid ... Read more